Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Dissolution Characteristics of A Gastro-Retentive Tablet System Containing Gabapentin

가바펜틴을 함유한 위체류성 정제의 제조 및 용출 평가

  • 유광희 (건일제약(주) R&D Center) ;
  • 이풍석 (건일제약(주) R&D Center) ;
  • 오의철 (서울대학교 에스티에이치팜(주))
  • Published : 2009.08.20
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this investigation was to develop a gastro-retentive(GR) dosage form of gabapentin and was to evaluate of its dissolution characteristics. GR tablet consists of expandable core tablet matrix and semi-permeable membrane coating. Poloxamer 407 and sodium bicarbonate were used to prepare the core matrix. Polyvinly acetate dispersion (Kollicoat $SR30D^{(R)}$) and polyvinyl alcohol-polyethylene glycol copolymer ((Kollicoat $IR^{(R)}$)) were employed to form the semi-permeable membrane. The GR tablets significantly expanded up to fivefold in simulated gastrointestinal fluids with no apparent damage of the coating membrane over 12 hours. Also, the swelling rate was controllable with the amount of sodium bicarbonate. The drug release was observed to be substantially sustained based on coating level. The release rate of gabapentin from the GR tablet was gradually slowed down as the coasting amount was increased. The gabapentin GR tablet with 8% coating level showed a pseudo-zero order release kinetics over 12 hours. These results suggest that this swellable GR tablet system having semi-permeable membrane coating can be applicable for hydrophilic drug substances like gabapentin.

Keywords

References

  1. A.A. Deshpande, C.T. Rhodes, N.H. Shah and A.W. Malick, Controlled-release drug delivery systems for prolonged gastric residence, Drug Dev. Ind. Pharm., 22(6), 531-539 (1996). https://doi.org/10.3109/03639049609108355
  2. A. Streuble, J. Siepmann and R. Bodmeier, Gastroretentive drug delivery systems, Expert Opin. Drug Deliv., 3(2), 217- 233 (2006) https://doi.org/10.1517/17425247.3.2.217
  3. Y.D. Tang, S.S. Venkatraman, F.Y.C. Boey and L.W. Wang, Sustained release of hydrophobic and hydrophilic drugs from a floating dosage form, J. Pharmaceutics, 336, 159- 165 (2007). https://doi.org/10.1016/j.ijpharm.2006.11.060
  4. E.A. Klausner, E. Lavy, M. Friedman, A. Hoffman, Expandable gastroretentive dosage form, J. Control. Release, 90, 142-162 (2003). https://doi.org/10.1016/S0168-3659(03)00203-7
  5. S. Frances, T.F. John, H.C. John, G.M. Luigi, L.S. Harbrans and S. Anne-marie, The use of citric acid to prolong the in vivo gastro retention of floating dosage form in the fasted state, Int. J. Pharmaceutics, 308, 8-13 (2006). https://doi.org/10.1016/j.ijpharm.2005.09.036
  6. B.N. Singh and H.N. Kim, Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention, J. Control. Release, 63, 235-259 (2000). https://doi.org/10.1016/S0168-3659(99)00204-7
  7. S.S. Ahmed and J.W. Ayres, Bioavailability of riboflavin from a gastric retention formulation, Int. J. Pharmaceutics, 330, 146-154 (2007). https://doi.org/10.1016/j.ijpharm.2006.09.021
  8. L. Meka, B. Kesavan, K.M. Chinnala, V. Vobalaboina, and M.R. Yamsanil, Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: In vitro evaluation, AAPS PharmSciTech, 9(2), 612-618 (2008). https://doi.org/10.1208/s12249-008-9090-4
  9. M. Oth, M. Franz, J. Timmermans and A. Moes, The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol. Pharm. Res. 9, 298-302 (1992) https://doi.org/10.1023/A:1015870314340
  10. E.A. Klausner, S. Eyal, E. Lavy, M. Friedman and A. Hoffmana, Novel levodopa gastroretentive dosage form: invivo evaluation in dogs, J.Control. Release, 88, 117–126 (2003). https://doi.org/10.1016/S0168-3659(02)00487-X
  11. A. Amin, T. Shah, D. Parikh and M Shah, Progress in swellable & low density excipients for prolonged gastric retention, Drug Delivery Tech., (Feb), 22-26 (2008).
  12. H.Y. Cho, H.A. Kang, E.J. Park, S.W. Oh, J.D. Moon and Y.B. Lee, Bioequivalence of Kuhnil Gabapentin capsule 300 mg to Neurontin capsule 300 mg (gabapentin 300mg), J. Kor. Pharm. Sci., 35(3), 193-199 (2005). https://doi.org/10.4333/KPS.2005.35.3.193
  13. T. Gordi, V. Cowles, Y.K. Chiang and E. Hou, Gabapentin pharmacokinetics after the administration of a gastric retentive formulation in postmenopausal women with hot flashes, Abstracts No. 1839, AAPS Annual Meeting, (2008).
  14. V. Cowles, G. Gusler, R. Gu, J. Louie-Helm, E. Hou and B. Berner, Dose Proportionality of Gabapentin Gastric Retentive Extended-Release Tablets in Beagle Dog, Abstracts No. 2109, AAPS Annual Meeting, (2006).
  15. T. Gordi, E. Hou, S. Kasichayanula and B. Berner, Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive?extended-release and immediate-release tablets: A randomized, open-label, multiple-dose, tree-way crossover, exploratory study in healthy subjects, Clinical Therapeutics, 30(5), 909-916 (2008). https://doi.org/10.1016/j.clinthera.2008.05.008
  16. M. Chavanpatil, P. Jain, S. Chaudhari, R. Shear and P. Vavia, Development of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation, Int. J. Pharm. 304, 178-184 (2005). https://doi.org/10.1016/j.ijpharm.2005.08.009